🇺🇸 FDA
Patent

US 10328130

Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions

granted A61KA61K31/337A61K38/47

Quick answer

US patent 10328130 (Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions) held by HALOZYME, INC. expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HALOZYME, INC.
Grant date
Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/337, A61K38/47, A61P, A61P19/00